Search Results

You are looking at 91 - 100 of 503 items for :

  • "Adjuvant therapy" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

HSR23-103: Pancreatic Cancer: The Impact of Early Connectivity and Coordination of Care on Retention and Time to Treat

Nicole Nardella, Matt Adams, Anjali Mahapatra, Diana Castillo, Sarah Hoffe, Dae Won Kim, Jason Fleming, and Pamela Hodul

adjuvant therapy (n=33). Of those that were resectable, borderline resectable, or locally advanced (n=191), 76% (145/191) had coordinated care secondary to their FC call; 68% of patients saw multiple interdisciplinary providers, with 25% occurring on the

Full access

HSR22-150: Lymph Node Evaluation of Post-Neoadjuvant Rectal Resection Specimens in Rectal Carcinoma

Saman S Karimi and Maria Gonzalez

determine the number of positive lymph nodes as an independent prognostic indicator in Stage II colorectal carcinoma, which prompts adjuvant therapy in these patients. This study aimed to assess the average number of lymph nodes in post-neoadjuvant rectal

Full access

Highlights of the NCCN Oncology Research Program

unresectable) colorectal cancer who have received prior treatment with a fluoropyrimidine (5-FU or capecitabine) and oxaliplatin or who have experienced a recurrence within 12 months of adjuvant therapy with a regimen that included oxaliplatin. For study

Full access

BPI20-014: Clinical Pathway and Education Implementation to Support Guideline Adherent Breast Cancer Care for Rural Women Under Age 50

Robin M. Lally, Elizabeth Reed, and Roksana Zak

-treatment assessments, consultations, considerations, neoadjuvant and adjuvant therapy and survivorship care. Oncology provider survey return rate was 25%. Results indicated satisfaction but changes needed to pathway design and content. Modified pathways were

Full access

HSR20-102: Quality Outcomes in Colon Cancer

Michelle Moskal and Neeharika S. Makani

, only 6.3% of high risk stage II and 45.5% of stage III patients received adjuvant therapy. Data showed 100% compliance with initiation of adjuvant 5-FU based chemotherapy within 12 weeks post surgery, which is recommended in high risk stage II and III

Full access

Highlights of the NCCN Oncology Research Program

) colorectal cancer who have received prior treatment with a fluoropyrimidine (5-FU or capecitabine) and oxaliplatin or who have experienced a recurrence within 12 months of adjuvant therapy with a regimen that included oxaliplatin. For study purposes, a cycle

Full access

The Current Status of Combined Radiotherapy and Chemotherapy for Locally Advanced or Resected Pancreas Cancer

Mary F. Mulcahy, Andrew O. Wahl, and William Small Jr.

1990 ; 66 : 56 – 61 . 7 Whittington R Bryer MP Haller DG . Adjuvant therapy of resected adenocarcinoma of the pancreas . Int J Radiat Oncol Biol Phys 1991 ; 21 : 1137 – 1143 . 8 Abrams RA . Adjuvant therapy for pancreatic

Full access

Adjuvant Treatment in Non-Small Cell Lung Cancer: Where Are We Now?

Rosalyn A. Juergens and Julie R. Brahmer

. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer . Eastern Cooperative Oncology Group . N Engl J Med 2000 ; 343 : 1217 – 1222 . 20. Mineo TC Ambrogi V

Full access

Role of Radiotherapy in the Management of Merkel Cell Carcinoma of the Skin

Roy H. Decker and Lynn D. Wilson

the addition of adjuvant therapy . J Clin Oncol 2005 ; 23 : 7236 – 7237 . 13. Wilson LD Gruber SB . Merkel cell carcinoma and the controversial role of adjuvant radiation therapy: clinical choices in the absence of statistical evidence

Full access

University of Michigan Comprehensive Cancer Center Opportunities for Improvement Project

Tara M. Breslin, Marcy Waldinger, and Samuel M. Silver

Center Educational Forum attendees illustrated a theme related to adjuvant therapy delay. Providers were surprised to learn that as many as 10% of patients were not recorded as receiving adjuvant endocrine therapy. Performance on this measure did not